TGFB1 and non-small cell lung carcinoma: In addition, we have demonstrated that combined treatment with the first-generation TKI gefitinib (or erlotinib) and the cyclic RGD peptide cilengitide and its derivatives have synergistic inhibitory effects on the growth of NSCLC cells and TGF-β1-induced EMT (Jeong and Kim, 2021; Jeong and Kim, 2022; Park et al., 2022; Seo and Kim, 2022).